Lenacapavir (LEN) has arrived in South Africa, and this injectable form of pre-exposure prophylaxis (PrEP) marks a major scientific milestone as it promises a near 100% effectiveness in preventing HIV. But there is a need to integrate injectable PrEP into broader sexual and reproductive health services.